Halozyme Therapeutics, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.02%145.500.0%$2678.66m
BNGOBioNano Genomics, Inc. -2.78%12.230.0%$2605.81m
GILDGilead Sciences, Inc. 0.00%68.161.0%$679.44m
AMGNAmgen, Inc. 0.00%257.101.3%$584.68m
REGNRegeneron Pharmaceuticals, Inc. 0.00%548.202.7%$502.24m
CRSPCRISPR Therapeutics AG 0.99%183.030.6%$482.88m
ALXNAlexion Pharmaceuticals, Inc. 0.47%162.082.0%$481.25m
ILMNIllumina, Inc. 0.00%421.003.5%$442.75m
NVAXNovavax, Inc. 0.00%131.4692.9%$427.52m
VRTXVertex Pharmaceuticals, Inc. 0.00%241.311.9%$385.00m
SRPTSarepta Therapeutics, Inc. -1.11%95.0413.8%$362.83m
BIIBBiogen, Inc. 0.01%275.571.7%$334.28m
BNTXBioNTech SE -0.24%110.350.0%$314.22m
EXASEXACT Sciences Corp. 0.00%153.9319.6%$267.92m
PACBPacific Biosciences of California, Inc. -1.28%35.497.4%$217.12m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.